NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 13 February 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Radha Todd (Chair) Present for all items
2. Alan Thomas Present for all items
3. Ana Duarte Items 1.1 to 5.3.2
4. Becky Pennington Present for all items
5. Dr Andrew Champion Items 5.1 to 6.2.2
6. Dr Craig Buckley Items 1.1 to 5.2.2
7. Dr Ian Bernstein Present for all items
8. Dr James Fotheringham (Vice-chair) Present for all items
9. Dr Patrick De Barr Present for all items
10. Dr Peter Baker-Gulliver Items 1.1 to 4.2.2
11. Dr Ravi Ramessur Present for all items
12. Dr Steve Edwards Present for all items
13. Hugo Pedder Present for all items
14. Jaqueline Tomlinson Present for all items
15. Mario Ganau Items 5.1 to 6.2.2
16. Prithwiraj Das Present for all items
17. Richard Ballerand Present for all items
18. Stella O’Brien Present for all items

NICE staff (key players) present

Janet Robertson, Associate Director Items 1.1 to 5.2.2

Thomas Feist, Project Manager Items 1.1 to 5.2.2

Joanna Richardson, Heath Technology Assessment Adviser Items 1.1 to 4.1.3

Catherine Spanswick, Heath Technology Assessment Analyst

Items 1.1 to 4.1.3

Mary Hughes, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Giacomo De Guisa, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

Ian Watson, Associate Director Items 6.1 to 6.2.2

Lizzie Walker, Heath Technology Assessment Adviser Items 6.1 to 6.2.2

Zain Hussain, Heath Technology Assessment Analyst Items 6.1 to 6.2.2

External assessment group representatives present

Sabine Grimm, Kleijnen Systematic Reviews Ltd Items 1.1 to 4.1.3

Robert Wolff, Kleijnen Systematic Reviews Ltd Items 1.1 to 5.1.3

Maiwenn Al, Kleijnen Systematic Reviews Ltd Items 5.1 to 5.1.3

Huiqin Yang, Kleijnen Systematic Reviews Ltd Items 5.1 to 5.1.3

Sarah Davies, School of Health and Related Research (ScHARR)

Items 6.1 to 6.1.3

Kate Ren, School of Health and Related Research (ScHARR)

Items 6.1 to 6.1.3

Clinical, Patient & NHS England experts present

Peter Clark, CDF Clinical Lead, NHS England Present for all items

Dr Patrick Medd, consultant haematologist, Clinical expert, nominated by RCP

Items 1.1 to 4.1.3

Dr Beth Phillips, Clinical Senior Lecturer/Hon. Consultant Haematologist, Clinical expert, nominated by RCP Items 1.1 to 4.1.3

Ceri Steele, patient advocate, Patient expert, nominated by OG Support Group

Items 5.1 to 5.1.3

Dr Kai-Keen Shiu, consultant medical oncologist, Clinical expert, nominated by Merk Sharp & Dohme Items 5.1 to 5.1.3

Dave Chuter, Patient Advocate/Advisor for Guts UK, Patient expert nominated by Guts UK

Items 5.1 to 5.1.3

Items 6.1 to 6.1.3

Prof. Was Mansoor, Professor of Medical Oncology, Clinical expert nominated by Merck Sharp & Dohme Items 6.1 to 6.1.3

Dr. Elizabeth Smyth, Consultant in Gastrointestinal Oncology, Clinical expert nominated by Royal College of Physicians Items 6.1 to 6.1.3

Helen West, Public Patient Involvement and Engagement Officer for Guts UK, Patient expert nominated by Guts UK Items 6.1 to 6.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair Radha welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Dominic Pivonka, Fiona MacPherson Smith, G.J. Melendez-Torres, Justin Daniels, Min Ven Teo, Mohit Sharma, Mohammed Farhat and Pratheeban Nambyiah.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 16th January 2024.

### Appraisal of [Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma [Review of TA540] [ID5084]](https://www.nice.org.uk/guidance/topic-selection/gid-ta11317)

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Merck Sharp & Dohme.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/topic-selection/gid-ta11317).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Peter Baker and Ana Duarte.
  2. Part 2 – Closed session (company representatives, clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Final Draft Guidance (FDG). The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/topic-selection/gid-ta11317>.

### Appraisal of [Pembrolizumab with chemotherapy for treating HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma [ID4030]](https://www.nice.org.uk/guidance/indevelopment/gid-ta11039)

* 1. Part 1 – Open session
     1. The chair, James Fotheringham, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Merck Sharp and Dohme.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11039).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Andrew Champion (Clinical), Steve Edwards (Cost), Alan Thomas (Lay).
  2. Part 2 – Closed session (company representatives, patient and clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11039>.

### Appraisal of [Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma [ID3742]](https://www.nice.org.uk/guidance/indevelopment/gid-ta10615)

* 1. Part 1 – Open session
     1. The chair, Radha Todd, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Merck Sharpe & Dohme.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10615).
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Radha Todd.
  2. Part 2 – Closed session (company representatives, patient and clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10615>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 12th March 2024 and will start promptly at 9:00.